Tag Archives: Oncology

Cellectis Q4 ’19 Earnings Update

On Thursday, March 5, Cellectis held their Q4 ‘19 earnings call, providing updates on their CAR-T clinical development program as well as their expanding manufacturing capabilities. In addition, the company provided further color around their recently-updated deal with Servier. Below, FENIX provides highlights and insights from the call, including their significance in the context of an increasingly-competitive CAR-T landscape.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Kite Acquires Rights to Certain Teneobio Antibodies for Multiple Myeloma CAR-T Therapies (including BCMA)

On Thursday April 2, Kite (a Gilead company) announced that it had entered into a license and collaboration agreement with Teneobio, granting Kite exclusive rights to specific antibodies targeting BCMA in multiple myeloma. Kite’s decision to re-enter the BCMA space follows Gilead’s discontinuation of its own BCMA CAR-T, KITE-585, in late 2018. Below, FENIX provides key takeaways and analysis from this new agreement, particularly in the context of Teneobio collaborations with other key players in the BCMA space: AbbVie and Poseida Therapeutics (who also has the backing of Novartis).

About The Author

mmaryniak1

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.